Matthias Ocker (Matias Knuuttila)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 17

Top Venues

Expert opinion on investigational drugs

Cancers

PloS one

International journal of molecular sciences

Boehringer Ingelheim Pharma GmbH and Co KG Biberach

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Boehringer Ingelheim Pharma GmbH and Co KG Biberach

Germany

Therapeutic Area Head Oncology :: Translational Medicine & Clinical Pharmacology

University of Marburg

Germany

Director / Full Professor :: Surgical Research

University Hospital Erlangen

Germany

Senior Research Fellow / Assistant Professor :: Medicine 1

University of Erlangen

Germany

Post-doctoral fellow :: Cellular and Molecular Physiology

University Hospital Erlangen

Germany

Post-doc :: Medicine 1

Publications

Dino Bekric, Tobias Kiesslich, Matthias Ocker, Martina Winklmayr, Markus Ritter, Heidemarie Dobias, Marlena Beyreis, Daniel Neureiter, Christian Mayr
The efficacy of ferroptosis-inducing compounds IKE and RSL3 correlates with the expression of ferroptotic pathway regulators CD71 and SLC7A11 in biliary tract cancer cells. PloS one 19 (4) (2024)
Dino Bekric, Tobias Kiesslich, Matthias Ocker, Martina Winklmayr, Markus Ritter, Heidemarie Dobias, Marlena Beyreis, Daniel Neureiter, Christian Mayr
The efficacy of ferroptosis-inducing compounds IKE and RSL3 correlates with the expression of ferroptotic pathway regulators CD71 and SLC7A11 in biliary tract cancer cells. PloS one 19 (4) (2024)
Dominik Kiem, Matthias Ocker, Richard Greil, Daniel Neureiter, Thomas Melchardt
Enhancing anti-CD274 (PD-L1) targeting through combinatorial immunotherapy with bispecific antibodies and fusion proteins: from preclinical to phase II clinical trials. Expert opinion on investigational drugs 33 (3) (2024)
Ulrike Rauh, Guo Wei, Michael Serrano-Wu, Georgios Kosmidis, Stefan Kaulfuss, Franziska Siegel, Kai Thede, James McFarland, Christopher T Lemke, Nicolas Werbeck, Katrin Nowak-Reppel, Sabine Pilari, Stephan Menz, Matthias Ocker, Weiqun Zhang, Kyle Davis, Guillaume Poncet-Montange, Jennifer A Roth, Douglas S Daniels, Virendar K Kaushik, Brian Hubbard, Karl Ziegelbauer, Todd R Golub
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models. Nature cancer (2024)
Dominik Kiem, Matthias Ocker, Richard Greil, Daniel Neureiter, Thomas Melchardt
Enhancing anti-CD274 (PD-L1) targeting through combinatorial immunotherapy with bispecific antibodies and fusion proteins: from preclinical to phase II clinical trials. Expert opinion on investigational drugs (2024)
Ulrike Rauh, Guo Wei, Michael Serrano-Wu, Georgios Kosmidis, Stefan Kaulfuss, Franziska Siegel, Kai Thede, James McFarland, Christopher T Lemke, Nicolas Werbeck, Katrin Nowak-Reppel, Sabine Pilari, Stephan Menz, Matthias Ocker, Weiqun Zhang, Kyle Davis, Guillaume Poncet-Montange, Jennifer A Roth, Douglas S Daniels, Virendar K Kaushik, Brian Hubbard, Karl Ziegelbauer, Todd R Golub
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models. Nature cancer (2024)
Dino Bekric, Tobias Kiesslich, Matthias Ocker, Martina Winklmayr, Markus Ritter, Heidemarie Dobias, Marlena Beyreis, Daniel Neureiter, Christian Mayr
The efficacy of ferroptosis-inducing compounds IKE and RSL3 correlates with the expression of ferroptotic pathway regulators CD71 and SLC7A11 in biliary tract cancer cells. PloS one 19 (4) (2024)
Dominik Kiem, Matthias Ocker, Richard Greil, Daniel Neureiter, Thomas Melchardt
Enhancing anti-CD274 (PD-L1) targeting through combinatorial immunotherapy with bispecific antibodies and fusion proteins: from preclinical to phase II clinical trials. Expert opinion on investigational drugs 33 (3) (2024)
Mari I Suominen, Matthias Ocker, Christoph A Schatz, Andreas Schlicker, Jukka Vääräniemi, Birgitta Sjöholm, Esa Alhoniemi, Bernard Haendler, Dominik Mumberg, Sanna-Maria Käkönen, Arne Scholz
Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model. International journal of molecular sciences 24 (3) (2023)
Mari I Suominen, Matthias Ocker, Christoph A Schatz, Andreas Schlicker, Jukka Vääräniemi, Birgitta Sjöholm, Esa Alhoniemi, Bernard Haendler, Dominik Mumberg, Sanna-Maria Käkönen, Arne Scholz
Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model. International journal of molecular sciences 24 (3) (2023)
Mari I Suominen, Matthias Ocker, Christoph A Schatz, Andreas Schlicker, Jukka Vääräniemi, Birgitta Sjöholm, Esa Alhoniemi, Bernard Haendler, Dominik Mumberg, Sanna-Maria Käkönen, Arne Scholz
Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model. International journal of molecular sciences 24 (3) (2023)
Peter Ellinghaus, Daniel Neureiter, Hendrik Nogai, Sebastian Stinzing, Matthias Ocker
Patient Selection Approaches in FGFR Inhibitor Trials-Many Paths to the Same End? Cells 11 (19) (2022)
Dino Bekric, Matthias Ocker, Christian Mayr, Sebastian Stinzing, Markus Ritter, Tobias Kiesslich, Daniel Neureiter
Ferroptosis in Hepatocellular Carcinoma: Mechanisms, Drug Targets and Approaches to Clinical Translation. Cancers 14 (7) (2022)
Christian Mayr, Tobias Kiesslich, Dominik Paul Modest, Sebastian Stintzing, Matthias Ocker, Daniel Neureiter
Chemoresistance and resistance to targeted therapies in biliary tract cancer: what have we learned? Expert opinion on investigational drugs 31 (2) (2022)
Matthias Ocker, Christian Mayr, Tobias Kiesslich, Sebastian Stinzing, Daniel Neureiter
Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future. Cancers 13 (7) (2021)
Matthias Ocker, Daniel Neureiter
Predicting the outcome of patients with hepatocellular carcinoma: new approaches beyond established clinical scoring systems. Expert review of gastroenterology & hepatology 15 (2) (2020)
Andreas Schneeweiss, Dagmar Hess, Markus Joerger, Andrea Varga, Stacy Moulder, Apostolia M Tsimberidou, Cynthia Ma, Sara A Hurvitz, Christine Rentzsch, Marion Rudolph, Silke Thiele, Oliver Boix, Gary Wilkinson, Eleni Lagkadinou, Matthias Ocker
Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. Cancers 11 (12) (2019)

Matthias Ocker.css-eqlu8i{font-size:small;padding-left:4px;} (Matias Knuuttila)

Publication Activity (10 Years)

Top Topics

Top Venues

Matthias Ocker (Matias Knuuttila)